AGN News and Press, Allergan plc From 10/14/19

DUBLIN , Oct. 14, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Allergan plc (NYSE: AGN) (the " ...

Allergan (NYSE: AGN ) resumed with Market Perform rating and $180 (7% upside) price target at Bernstein. More news on: Allergan plc, Amgen Inc., Biogen Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to...

On the good news front in today's series, Stealth BioTherapeutics ( MITO ) and Alexion Pharmaceuticals ( ALXN ) have agreed to co-develop and commercialize elamipretide for mitochondrial diseases. Elamipretide, an inner mitochondrial membrane-targeting therapeutic, is Stealth BioTherapeutics...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

DUBLIN , Oct. 11, 2019 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology and Molecular Partners (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin®...

Biotech is in the doldrums. The SPDR S&P Biotech ETF  declined 18% in the past six months, and money continues to flow out of the sector. While several biotechs managed to IPO in September and October , it's not all roses. ADC Therapeutics pulled its plans to list citing market...

Quick Take Oyster Point Pharma (OYST) has filed to raise gross proceeds of $85 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing treatments for ocular surface diseases. OYST has produced very promising results in Phase 2b trials for its lead ca...

DUBLIN , Oct. 10, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced a national education campaign called My Glaucoma. The campaign is designed to help people understand the burden of li...

Nestle S.A. ( OTCPK:NSRGY ) subsidiary Galderma announces positive results from a Phase 2 clinical trial evaluating QM1114, its ready-to-use liquid formulation of botulinum toxin type A, for the treatment of glabellar lines (frown lines). More news on: Nestlé S.A., Allergan plc, Evo...